Comparative bioavailability of a newly developed Irbesartan 300 mg containing preparation

• Váldodahkkit: Petrov Andrey D. (Dahkki), Gatchev Emil M. (Dahkki), Kalinov Krasimir B. (Dahkki), Filipova Elena P. (Dahkki), Uzunova Katya H. (Dahkki), Vekov Toni Y. (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Srpsko lekarsko drustvo, 2018-01-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Introduction: Irbesartan (CAS registry: 138402-11-6) is a potent, orally active, selective antagonist of the angiotensin II receptors (type AT1) indicated for the treatment of arterial hypertension and chronic heart failure. Aim: The objective of the present study was to demonstrate the bioequivalen...